Limits...
Novel research translates to clinical cases of schizophrenic and cocaine psychosis.

Nunes JV, Broderick PA - Neuropsychiatr Dis Treat (2007)

Bottom Line: Their neurochemical neuronal mechanisms of action, as shown in preclinical and clinical studies, involve primarily dopaminergic dysfunction and, secondarily, neuroadaptive effects that seem to involve central serotonergic function.Also, controlled clinical studies have shown that risperidone, an atypical antipsychotic medication, is successful in the treatment of cocaine dependence and withdrawal (Smelson et al 1997, 2002; Grabowski et al 2000).Furthermore, the availability and effectiveness of long-acting risperidone in injectable form opens new possibilities for the long-term management of both disorders.

View Article: PubMed Central - PubMed

Affiliation: Department of Behavioral Medicine, The City University of New York Medical School, The Sophie Davis School of Biomedical Education, NY, NY, USA. nunes@med.cuny.edu

ABSTRACT
Pharmacotherapies for schizophrenic and cocaine psychoses are complex but similar because of similarities in their brain neurochemistry and behavioral outcomes. Their neurochemical neuronal mechanisms of action, as shown in preclinical and clinical studies, involve primarily dopaminergic dysfunction and, secondarily, neuroadaptive effects that seem to involve central serotonergic function. Behavioral outcomes of both disorders include hyperactivity and antipsychotic medications can ameliorate psychotic symptoms. Patients with both disorders often arrive at emergency departments and present floridly psychotic with a predominance of positive symptoms, often prompting physicians to select a typical antipsychotic medication such as haloperidol. While this has become conventional wisdom, we believe that to use an atypical antipsychotic medication, such as risperidone, in the treatment of both psychoses is quite rational for long-term management of both positive and negative symptoms. Also, controlled clinical studies have shown that risperidone, an atypical antipsychotic medication, is successful in the treatment of cocaine dependence and withdrawal (Smelson et al 1997, 2002; Grabowski et al 2000). Furthermore, the availability and effectiveness of long-acting risperidone in injectable form opens new possibilities for the long-term management of both disorders. In this paper, we present data which show that the use of risperidone is plausible for effective pharmacotherapy of schizophrenic and cocaine psychoses.

No MeSH data available.


Related in: MedlinePlus

Day 2 Adult male Sprague-Dawley laboratory rats who received cocaine (10 mg/kg i.p.) and co-administered risperidone (2 mg/kg s.c.) and cocaine (10 mg/kg i.p.) were monitored one day after drug administration to detect possible withdrawal effects with respect to ambulations. Neither cocaine nor risperidone showed significant second-day effects over baseline (unpaired t-test, p = 0.2478 and p = 0.3605, respectively).Note: First point in both groups denotes “novelty to chamber” effects.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2655083&req=5

f3B-ndt-3-475: Day 2 Adult male Sprague-Dawley laboratory rats who received cocaine (10 mg/kg i.p.) and co-administered risperidone (2 mg/kg s.c.) and cocaine (10 mg/kg i.p.) were monitored one day after drug administration to detect possible withdrawal effects with respect to ambulations. Neither cocaine nor risperidone showed significant second-day effects over baseline (unpaired t-test, p = 0.2478 and p = 0.3605, respectively).Note: First point in both groups denotes “novelty to chamber” effects.


Novel research translates to clinical cases of schizophrenic and cocaine psychosis.

Nunes JV, Broderick PA - Neuropsychiatr Dis Treat (2007)

Day 2 Adult male Sprague-Dawley laboratory rats who received cocaine (10 mg/kg i.p.) and co-administered risperidone (2 mg/kg s.c.) and cocaine (10 mg/kg i.p.) were monitored one day after drug administration to detect possible withdrawal effects with respect to ambulations. Neither cocaine nor risperidone showed significant second-day effects over baseline (unpaired t-test, p = 0.2478 and p = 0.3605, respectively).Note: First point in both groups denotes “novelty to chamber” effects.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2655083&req=5

f3B-ndt-3-475: Day 2 Adult male Sprague-Dawley laboratory rats who received cocaine (10 mg/kg i.p.) and co-administered risperidone (2 mg/kg s.c.) and cocaine (10 mg/kg i.p.) were monitored one day after drug administration to detect possible withdrawal effects with respect to ambulations. Neither cocaine nor risperidone showed significant second-day effects over baseline (unpaired t-test, p = 0.2478 and p = 0.3605, respectively).Note: First point in both groups denotes “novelty to chamber” effects.
Bottom Line: Their neurochemical neuronal mechanisms of action, as shown in preclinical and clinical studies, involve primarily dopaminergic dysfunction and, secondarily, neuroadaptive effects that seem to involve central serotonergic function.Also, controlled clinical studies have shown that risperidone, an atypical antipsychotic medication, is successful in the treatment of cocaine dependence and withdrawal (Smelson et al 1997, 2002; Grabowski et al 2000).Furthermore, the availability and effectiveness of long-acting risperidone in injectable form opens new possibilities for the long-term management of both disorders.

View Article: PubMed Central - PubMed

Affiliation: Department of Behavioral Medicine, The City University of New York Medical School, The Sophie Davis School of Biomedical Education, NY, NY, USA. nunes@med.cuny.edu

ABSTRACT
Pharmacotherapies for schizophrenic and cocaine psychoses are complex but similar because of similarities in their brain neurochemistry and behavioral outcomes. Their neurochemical neuronal mechanisms of action, as shown in preclinical and clinical studies, involve primarily dopaminergic dysfunction and, secondarily, neuroadaptive effects that seem to involve central serotonergic function. Behavioral outcomes of both disorders include hyperactivity and antipsychotic medications can ameliorate psychotic symptoms. Patients with both disorders often arrive at emergency departments and present floridly psychotic with a predominance of positive symptoms, often prompting physicians to select a typical antipsychotic medication such as haloperidol. While this has become conventional wisdom, we believe that to use an atypical antipsychotic medication, such as risperidone, in the treatment of both psychoses is quite rational for long-term management of both positive and negative symptoms. Also, controlled clinical studies have shown that risperidone, an atypical antipsychotic medication, is successful in the treatment of cocaine dependence and withdrawal (Smelson et al 1997, 2002; Grabowski et al 2000). Furthermore, the availability and effectiveness of long-acting risperidone in injectable form opens new possibilities for the long-term management of both disorders. In this paper, we present data which show that the use of risperidone is plausible for effective pharmacotherapy of schizophrenic and cocaine psychoses.

No MeSH data available.


Related in: MedlinePlus